Publication in Kidney Medicine Highlights Benefits of DSR 2.0 for Sequana Medical’s Direct Sodium Removal Heart Failure Program and Board Composition Update
Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces the publication in the prestigious peer-reviewed journal Kidney Medicine regarding the Company’s proprietary DSR 2.0, used in its Direct Sodium Removal program, a potential therapy for the treatment of cardiorenal syndrome and diuretic resistance in heart failure. The publication can be accessed here.
Dr. Jeffrey Testani, Associate professor at Yale University commented: “This manuscript describes the pre-clinical to first in-human development of the first solution specifically designed to remove sodium from our patients. All commercially available peritoneal solutions were designed with a primary goal of cleaning toxins from the blood, whereas DSR 2.0 was created to specifically meet the unmet clinical need of removing salt and water. The results were truly impressive with ~4X greater sodium removal with DSR 2.0 compared to a commercially available solution. This new tool will allow significant improvement in the care of our diuretic resistant cardio-renal syndrome patients.”
Ian Crosbie, Chief Executive Officer of Sequana Medical, added: “We are delighted with this publication highlighting the improved safety and efficacy of our proprietary DSR 2.0 vs dextrose-based approaches. These results build on clinical proof of concept published in European Journal of Heart Failure for DSR as a potential drug therapy for diuretic resistance and cardiorenal syndrome in heart failure using our DSR 1.0 product. The results of the first patients in the US MOJAVE study using our advanced DSR 2.0 product support the enhance efficacy demonstrated in this excellent paper. We believe DSR’s ability to virtually eliminate the need for loop diuretics for many months post-treatment represents a breakthrough in treatment options, and address one of the leading drivers of healthcare costs.”
The paper details pre-clinical and clinical studies to develop an optimised solution for removal of sodium and water. This builds upon the initial proof of concept studies published in Circulation demonstrating that DSR 1.0 increased sodium removal four-fold compared to commercially available peritoneal dialysis solutions. In previous experiments in humans, one litre of DSR 1.0 with a dwell of two hours removed on average 4.5g of sodium with a net ultrafiltration volume of 700mL; whereas in this paper, 0.5L of DSR 2.0 with a dwell of 24 hours removed ~9g of sodium with a net ultrafiltration volume of 2,500mL.
In line with Sequana Medical’s drive to improve cost efficiency and to meet the Belgian requirements for gender diversity prior to January 1, 2025, Douglas Kohrs and Kenneth MacLeod have stepped down from the board.
Pierre Chauvineau, Chairman of the board of Directors of Sequana Medical commented: “We thank Doug and Ken for their hard work and great contributions to the company, and wish them well. Their input has been key in bringing Sequana Medical to where it is today.”